TRAIN-HEART is rated 3 out of 5 in the category biotechnology. Read and write reviews about TRAIN-HEART. The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
Company size
11-50 employees
Headquarters
Maastricht, Limburg